Detecting Tumors’ Resistance to Radiation Therapy

Johns Hopkins research illuminates potential of inHealth approach

Published in Dome - Dome March/April 2019

A new Johns Hopkins study offers promise toward someday being able to noninvasively examine changes in cancerous tumors to determine whether they will respond to radiation therapy before starting the treatment.

The findings, published Feb. 28 in Cancer Research, can potentially help identify subsets of patients who are best suited for radiation treatment, thereby reducing medical overtreatment and helping some patients avoid the adverse effects of radiation.

“Our eventual hope is to be able to predict a patient’s response before radiation therapy even begins. If we knew in advance that the patient’s tumor is resistant, appropriate changes to the treatment plan such as escalation of radiation doses can be implemented. On the other hand, if a tumor is found to be more sensitive, the dose may be adjusted to a level that would still control the tumor but greatly reduce the risk of normal tissue complications,” says Johns Hopkins biomedical engineer Ishan Barman. One of the study’s corresponding authors, Barman holds joint appointments at the Sidney Kimmel Comprehensive Cancer Center and in the Russell H. Morgan Department of Radiology and Radiological Science, and is an assistant professor in the Department of Mechanical Engineering.

Identifying subsets of patients to help find the best treatment is an example of the precision medicine approach that Johns Hopkins Medicine uses to improve health care while cutting its costs, according to Antony Rosen, vice dean for research and director of Johns Hopkins inHealth, the institution’s precision medicine effort. (In a viewpoint published recently in The Journal of Clinical Investigation, Rosen recommends a redefinition of precision medicine to ensure its success.)

In typical radiation therapy, small doses of radiation are delivered over a period of five to seven weeks. There’s currently no definitive way to predict treatment response before therapy or even in the early weeks of therapy. The earliest clinicians can examine tumor shrinkage is two to three weeks after therapy, using computed tomography and MRI scans.

While other studies have investigated molecular changes in tumors as a way to preemptively identify tumors that won’t respond to radiation treatment, Barman’s team says its research is unique. Team members studied multiple types of cancers and used smaller doses of radiation, which more accurately reflects current radiation therapy practices.

“Previous researchers used a single large dose of radiation, resulting in biomolecular changes that don’t accurately mimic the subtle changes caused by smaller doses delivered over longer periods of time,” says Santosh Paidi, a Johns Hopkins University mechanical engineering graduate research assistant and the study’s first author.

In this study, researchers from Johns Hopkins, the University of Arkansas and the University of Arkansas for Medical Sciences used Raman spectroscopy, employing laser light to examine how molecules vibrate. With that method, they could characterize changes in the biochemical composition of a tumor and its environment. This method, the researchers say, requires only a low-power laser and doesn’t need additional sample preparation. Such technologies enable holistic examination of the complex biological processes of radiation treatment.

To test the difference in response from tumors that are sensitive to radiation and those that are resistant, the researchers used cell lines of both resistant and sensitive tumors from human lung cancers as well as head and neck cancers to grow tumors in mice.

After the tumors grew to a certain size, the research team removed them and scanned them with a Raman spectroscopy system. All four tumor types showed changes in response to small doses meant to replicate clinical radiation therapy practice in humans and given over the course of two weeks.

The researchers also found consistent changes in lipid and collagen content in lung as well as head and neck tumors.

For the second part of the experiment, the research team examined untreated lung tumors. Raman spectroscopy provided data that allowed the researchers to distinguish between radiation-resistant and radiation-sensitive tumors, thus providing key insight into the roles different molecules may play in making tumors resistant to radiation. 

The research team found subtle differences in each tumor type’s spectrographic signature. By analyzing these patterns, the researchers created an algorithm that could identify radiation resistance and sensitivity with a 97 percent success rate.

“This is only the first step of a larger research endeavor to determine how head and neck cancer tumors respond to radiation,” says Barman. “The ultimate goal is to build a miniature probe that can fit into a laryngoscope. Hopefully in the future, then, when clinicians perform an endoscopy and looks at a patient’s cancerous tumor, they’ll be able to determine whether that tumor will even respond to radiation therapy, and that can improve treatment plans.”

Matching Patient with Treatment

A new analytics platform will help Johns Hopkins doctors provide care that is tailored to individual patients.

Matching Patient with Treatment_edit